Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $6.76 for the day, down -2.59% from the previous closing price of $6.94. In other words, the price has decreased by -$2.59 from its previous closing price. On the day, 3.94 million shares were traded. RXRX stock price reached its highest trading level at $6.94 during the session, while it also had its lowest trading level at $6.5901.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.07 and its Current Ratio is at 6.07. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 15 ’24 when Borgeson Blake sold 11,447 shares for $6.67 per share. The transaction valued at 76,326 led to the insider holds 7,089,007 shares of the business.
Burrell Terry-Ann bought 404,688 shares of RXRX for $2,693,813 on Oct 17 ’24. On Oct 15 ’24, another insider, Borgeson Blake, who serves as the Director of the company, bought 11,447 shares for $6.67 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 1970729344 and an Enterprise Value of 1565454848. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.69 while its Price-to-Book (P/B) ratio in mrq is 3.25. Its current Enterprise Value per Revenue stands at 31.539 whereas that against EBITDA is -4.29.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $4.97. The 50-Day Moving Average of the stock is 0.89%, while the 200-Day Moving Average is calculated to be -22.90%.
Shares Statistics:
RXRX traded an average of 4.90M shares per day over the past three months and 4303630 shares per day over the past ten days. A total of 291.36M shares are outstanding, with a floating share count of 226.82M. Insiders hold about 22.15% of the company’s shares, while institutions hold 76.19% stake in the company. Shares short for RXRX as of 1727654400 were 62578756 with a Short Ratio of 12.76, compared to 1724976000 on 56030343. Therefore, it implies a Short% of Shares Outstanding of 62578756 and a Short% of Float of 30.91.
